CN Patent

CN105228615A — 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂

Assigned to Lu Meina Pharmaceuticals · Expires 2016-01-06 · 10y expired

What this patent protects

本文提供通过向需要其的个体施用治疗有效量的顶端钠依赖性胆汁酸转运蛋白抑制剂(ASBTI)或其药学上可接受的盐治疗或改善巴雷特食管的方法。本文提供通过向需要其的个体施用治疗有效量的ASBTI或其药学上可接受的盐治疗或改善胃食管返流疾病(GERD)的方法。还提供用于治疗或改善与巴雷特食管或GERD相关的症状或并发症的方法，该方法包括向需要其的个体施用治疗有效量的ASBTI或其药学上可接受的盐。

USPTO Abstract

本文提供通过向需要其的个体施用治疗有效量的顶端钠依赖性胆汁酸转运蛋白抑制剂(ASBTI)或其药学上可接受的盐治疗或改善巴雷特食管的方法。本文提供通过向需要其的个体施用治疗有效量的ASBTI或其药学上可接受的盐治疗或改善胃食管返流疾病(GERD)的方法。还提供用于治疗或改善与巴雷特食管或GERD相关的症状或并发症的方法，该方法包括向需要其的个体施用治疗有效量的ASBTI或其药学上可接受的盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN105228615A
Jurisdiction
CN
Classification
—
Expires
2016-01-06
Drug substance claim
No
Drug product claim
No
Assignee
Lu Meina Pharmaceuticals
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.